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Proteomic technology enables large-scale profiling of global
protein expression and systematic monitoring of proteins
and protein variation in the diverse landscape of cellular
translation. Therefore, it enables in-depth analyses of host
and pathogen interactions. The emergence of databases of
complete human and animal genomes and computer
modeling now enable protein-level analysis of proteomes in
samples from diverse biomedical sources by coupling
various proteomic strategies with state-of-the-art mass
spectrometry (MS) [1,2]. The diverse and intricate protein
components identified in proteomes of biological tissues
and cells can then be compared with in silico peptide maps
derived from enzyme-digested proteins or genomic data-
bases deposited in assorted databanks. Thus, instead of
using conventional analyses of protein chemistry for global
characterization of cellular proteins, researchers are now
combining proteomic/genomic analyses with fast-evolving
MS instrumentation. Methods of characterizing and
sequencing genomic alterations in various biological speci-
mens are also rapidly improving. The next logical step is
identifying functional changes in the human proteome
caused by genomic alterations or other environmental
factors and then performing clinical studies to identify and
validate protein biomarkers of these changes.
Integrating advanced genomic analysis with proteomic
characterization not only has great potential use for
discovering useful biomarkers, but it may also drive the
development of new diagnostics methods and therapies.
Increasing use of these new approaches thus sets the stage
for development of new molecularly targeted cancer in-
terventions [3].
Tumor heterogeneity is widely considered the main
cause of ineffective and unsuccessful cancer treatment.
Therefore, an improved understanding of the effects of
complex proteomes in cancer cell microenvironments is
urgently needed [4]. Novel applications of proteomic
technology, particularly in translational medicine, have
been reported in clinical studies of cancer [5]. For
example, coupling proteomic approaches with bio-
informatic mining of the human cancer genome has proven
useful for elucidating molecular mechanisms related to
tumorigenesis. Many other novel applications of proteoge-
nomic and onco-proteomic methods have been reported in
the recent literature [6e9].
Hepatocellular carcinoma (HCC) is the third and the first
leading cause of cancer-related mortality worldwide and in
Taiwan, respectively [10,11]. A major etiological factor in
HCC is cirrhosis, which is usually caused by chronic infection
with hepatitis B or C virus, nonalcoholic fatty liver disease,and alcohol abuse [12]. Many HCC patients are initially
diagnosed with chronic liver diseases, resulting in replace-
ment of normal tissue with fibrous tissue [13] and gradual
progression to an incurable stage of HCC. The widely varying
pathological manifestations and etiologies of HCC as well as
its high potential for multiple genomic aberrations have
resulted in an obstinate treatment for HCC. The biggest
therapeutic advance in the past decade, which is the
introduction of the multi-kinase inhibitor sorafenib, only
extends life expectancy by 8e11 months [14]. Because of its
limited therapeutic efficacy, improved molecularly targeted
therapies, such as therapies for inhibiting cyclin-dependent
kinase 9 [15] or MET [16], are urgently needed. Moreover,
barriers to developing effective therapies for HCC highlight
the need for new noninvasive biomarkers for early detection
and diagnosis/prognosis in this refractory class of liver
cancer.
Current cancer diagnostic methods still rely on tests for
classic cancer biomarkers (e.g., tumor antigen markers
carbohydrate antigen-125, carbohydrate antigen 19-9, and
carcinoembryonic antigen combined with histopathological
analysis of tissue biopsy samples. The specificity and sensi-
tivity of these methods are inconsistent [17]. Currently,
abdominal ultrasonography and measurement of serum a-
fetoprotein are the two main tools for detecting HCC at an
early stage [18]. However, the expertise needed to perform
abdominal ultrasonography and the poor sensitivity and
specificity of a-fetoprotein have limited their diagnostic and
prognostic use. By contrast, recent developments in prote-
omic technologies now enable reliable high-throughput
identification of protein mixtures in biological tissues,
which provides a good basis for understanding the complex
proteomic profiles of various biological samples, including
tissues, cells, plasma, and urine [19,20]. Moreover, quali-
tative and quantitative studies of proteins by rapidly
evolving state-of-the-art proteomic methodologies such as
shotgun proteomics enable comprehensive global analyses
of protein expression profiles in various cancer types,
including HCC [21e23]. Although researchers have used
onco-proteomics to identify biomarkers, its use for identi-
fying tumor-specific peptides is limited due to the com-
plexities of tumor genomes and transcriptomes such as point
mutations, copy-number aberrations, unusual splicing vari-
ants, and gene fusion [24,25]. Extensive genomic studies
performed in recent years indicate that novel genomic
amplifications, mutations, and deletions occur frequently in
HCC [26,27]. For example, a novel HCC-promoting gene,
FGF19, is reportedly amplified in HCC cells harboring the
11q13.3 amplicon [28]. Sawey et al [28] further showed that
11q13.3 amplification could be a useful biomarker of the
response to anti-FGF19 therapy. Advances in gene-
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molecular classification of HCCs into defined subgroups
based on genomic and proteomic analysis data, which pro-
vide a good basis for performing more informative clinical
trials [29]. Because it links cancer proteomics to genomics
and transcriptomics, onco-proteogenomics is considered an
important new research tool and strategy. By integrating
and applying advanced methods of detecting various tumor-
specific changes in the proteome, onco-proteogenomics can
provide, an in-depth understanding of tumor initiation,
progression, and responses to treatment [24,25,30]. By
incorporating MS-generated data with genomic information,
onco-proteogenomics also enables a comprehensive under-
standing of how cellular networks and canonical signaling
pathways are dysregulated in various cancer types. Several
previous studies have applied multiple proteogenomic stra-
tegies to characterize cell lines and primary tumors in
colorectal, gastric and other cancer [30e32].
The objective of this study was to identify effective and
noninvasive diagnostic biomarkers for early detection of
HCC. Potential biomarker candidates were identified by
characterizing and comparing urinary proteins between
diseased and control groups by gel-free shotgun proteomic
analysis coupled with stable isotope dimethyl labeling and
nanoscale liquid chromatographyetandem MS (nano-
LCeMS/MS) as reported previously [33e38]. We also report
the use of our recently developed strategy for identifying
biomarkers by combining conventional cancer genomics
with rapidly evolving proteogenomic methods [24,25], that
is, onco-proteogenomics. Using the proposed strategy to
detect tumor-specific changes in human cancer genomes
and transcriptomes provides important insights and enables
a comprehensive understanding of how oncogenic signaling
pathways are dysregulated in various cancer types such as
human HCC, which we report herein, and gastric cancer,
which we will report in a future study.Basic MS-based proteomic methodologies and
platforms
Sample collection
All procedures used in this study were approved by the
Clinical Research Ethics Committee at Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan, and written
informed consent was obtained from all participants. Forty
patients who had been diagnosed with HCC but had never
received cholecystectomy were enrolled in the disease
group. Another 40 patients who had no history of HCC
diagnosis but had received cholecystectomy were enrolled
in the normal control group. Urine samples (50 mL) were
collected from each participant and concentrated by
centrifugation. After protein assay using Coomassie Protein
Assay Reagent, each sample was stored at 80C until
further analysis.
Gel-free shotgun MS-based proteomics
MS-based proteomic technology has progressed rapidly in
the past decade. The main strategies for performingproteomic studies can be classified as bottom-up and top-
down approaches. Bottom-up approaches characterize
proteins by analyzing peptides released through proteoly-
sis. By contrast, top-down approaches use direct electro-
spray ionization of proteins followed by gas-phase
fragmentation for MS analysis [39e41].
A mixture of proteins, such as a whole cellular prote-
ome, can be analyzed by a bottom-up approach known as
shotgun proteomics. First, intact proteins are either
chemically or enzymatically cleaved to peptides. The
resulting peptides are typically separated by LC followed
by MS/MS, which generates characteristic fragmentation
patterns of peptides [42]. Peptides are identified by
comparing the peptide MS/MS pattern with theoretical MS/
MS patterns generated by in silico digestion of a protein
database. Proteins are then identified by mapping the
identified peptides back to proteins based on a user-
defined protein database. Because peptides can be
either uniquely assigned to a single protein or shared by
more than one protein, the identified proteins require
further scoring and grouping according to their peptides.
Sophisticated computational tools have been developed to
enable automatic analysis of vast amounts of data gener-
ated by shotgun proteomics.
For a complex protein mixture such as the entire cell
lysates, multidimensional LC is the shotgun proteomic
approach typically used to reduce sample complexity and
to increase the dynamic range of protein identification
[22,23]. Currently, multidimensional LC is routinely used
for femtomolar detection and measurement of thousands
of proteins, within several hours. In recent years, gel-free
shotgun proteomics combined with LC-MS/MS has been
the preferred method of analyzing complex samples
because it is highly automated and has high throughput and
sensitivity. Recently developed MS methods can be used not
only to identify proteins in a mixture, but also to determine
relative levels of protein expression in one or more sam-
ples. That is, gel-free shotgun proteomics has paved the
way to quantitative proteomics by circumventing conven-
tional semi-quantitative gel-based proteomic methods
based on image analysis of protein spots on two-
dimensional gels. In this study, protein expression in urine
samples from HCC patients and normal controls was pro-
filed by shotgun proteomics using nanoLCeMS/MS and sta-
ble isotope dimethyl labeling (described below), followed
by protein database searches for, and characterization and
quantification of, detected biomarkers.Stable isotope dimethyl labeling-based quantitative
proteomics
Isotope dimethyl labeling is applicable for any protein
sample and, compared to other quantitative methods based
on stable isotope labeling, is simpler, more reliable, and
more cost-effective [43]. This proteomic method was
developed in 2003 by Hsu et al [44]. As shown in the
following chemical equation, heavy (deuterium) and light
(hydrogen) isotope formaldehyde were reacted with pri-
mary amines (the N terminus and the side chain of lysine
residues) in a peptide mixture to form Schiff bases.
Figure 1. Potential urinary biomarkers for HCC were identified by
diagnosed with HCC and from normal controls (nZ 44) were ana
further analyzed and selected using genomic/transcriptomic appro
538 S.-H. Chiou, K.-T. LeeReduction of cyanoborohydride then generated dimethyl-
amine groups as shown below.
Isotope dimethyl labeling provides high reaction effi-
ciency and selectivity without major byproducts [45].
Triplex or even more labeling tags have been used in
multiplex isotope dimethyl labeling methods developed to
facilitate time course studies and comparisons of multiple
states (e.g., doseeresponse curves), or multiple disease
stages [46]. The multiplex isotope labeling strategy im-
proves protein quantification accuracy by analyzing multiple
protein samples in one experiment, which minimizes varia-
tion in LC separation and MS detection procedures [47,48].an onco-proteogenomic approach. Urine samples from patients
lyzed by quantitative proteomics. Identified candidates were
aches. HCCZ hepatocellular carcinoma.
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proteomics for monitoring cancer progression in
personalized medicine
Trends in protein expression dependent on disease pro-
gression can be identified by signals in the MS1 spectra of
individual isotope tags, which represent the protein
expression levels in corresponding disease stages. A protein
is identified by its exact peptide mass in the MS1 scan
(precursor mass) and by its characteristic fragmentation
patterns in the MS2 scan. In this study, peptide and frag-
ment masses were identified by peak lists converted from
the nanoLC-MS/MS spectra. Specifically, the Mascot pro-
gram (http://www.matrixscience.com) was used for
searches/comparisons against the Homo sapiens taxonomy
in the SwissProt databases for exact matches in a bioin-
formatics database [49,50]. Bioinformatic analyses of
signaling pathways, proteineprotein interaction networks,
and clustering of time-dependent up/downregulation pro-
tein markers were then used to elucidate mechanisms un-
derlying the progression of the studied disease.Gene ontology and pathway analysis
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) Bioinformatics Resources [51] were used
to perform gene ontology (GO) analyses to determine which
functional processes were differentially represented in the
protein list obtained from quantitative proteomic analyses
of urine samples from HCC patients and normal controls.Figure 2. Flow-chart and experimental schemes of the procedure
peptides were differentially stable isotope dimethyl-labeled and c
shotgun analysis of proteome changes in clinical samples of urine fr
performed by hydrophilic interaction liquid chromatography (H
phyetandem mass spectrometry coupled with stable isotope dimeThe up- and downregulated proteins from proteomic anal-
ysis were used for GO analysis.
Genomic and transcriptomic data analysis
All cancer genome datasets and bioinformatics tools used to
visualize different parameters in analyses of genomic and
transcriptomic data were accessed through the MSKCC cBio
Core homepage (www.cbioportal.org) [52]. Co-occurring
gene amplifications in HCC were identified by analyzing the
Cancer Genome Atlas (TCGA; 193 tumor samples). Compar-
ison of copy number aberrations and gene expression was
also based on available TCGA datasets for HCC.
Preliminary results obtained by shotgun
quantitative proteomics and onco-
proteogenomic analyses
Many studies have investigated methods of diagnosis and
early detection of HCC based on hepatitis B virus surface
antigen concentrations in serum and in urinary aflatoxin
metabolites. Several epidemiological studies have indicated
that environmental factors, including alcohol use, tobacco
use, anddietary exposure to aflatoxins, at least partly explain
the high incidence of HCC [53]. Some biomarkers that have
shown high specificity and accuracy for detecting HCC are not
applicable for all environmental and genetic causal factors in
HCC [54]. Additionally, potential biomarkers may be present
at low concentrations whereas interfering proteins may be
abundant in a wide dynamic range.s used for quantitative proteomics. Upon enzymatic digestion,
ombined prior to desalting and fractionation. The quantitative
om hepatocellular carcinoma patients and normal controls was
ILIC)-C18 peptide separation and nano-liquid chromatogra-
thyl labeling.
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onco-proteogenomic approach to compare biomarkers from
tissues and urine of HCC patients and normal controls [55].
The current study used an optimized shotgun-based quanti-
tative proteomic strategy to analyze urinary proteins in each
of 44 pairs of HCC patients and normal controls. Further
cross-analyses of these proteomic results with genomic and
transcriptomic data (Figure 1) revealed urinary HCC bio-
markers with potential use individually or in combination
with other biomarkers. As Figure 2 shows, two major protein
biomarker candidates were identified with high confidence
levels in quantitative proteomic analysis of differentially
expressed proteins in urine samples from HCC patients.Figure 3. Hierarchical clustering of proteins that showed
significant (p < 0.05) differences in expression between urine
samples from HCC patients and from healthy controls (nZ 44).
Wilcoxon signed-rank test with paired setting was used to
calculate p values. Heat map was constructed by R package
“pheatmap” (R Foundation foe Statistical Computing Vienna,
Austria) with default settings. The value shown in the heatmap
is the quantification ratio (D/H) of peptides identified in urine
from HCC patients (deuterium labeling) to that in urine from
normal controls (hydrogen labeling). HCCZ hepatocellular
carcinoma.Quantitative proteomic analysis of differentially
expressed proteins in urine samples from HCC
patients by a shotgun approach
Figure 2 shows that urinary proteins were characterized
and compared between the disease and control groups
(nZ 44) by using gel-free shotgun proteomic analysis
coupled with stable isotope dimethyl labeling [23,44] and
nanoLC-MS/MS [46]. Differentially released proteins were
identified by dimethyl labeling, enzyme digestion, and
peptide mass fingerprinting followed by comparison of
urinary-peptide quantification ratios (D/H) between HCC
patients (deuterium labeling) and normal controls
(hydrogen labeling). Approximately 1000 proteins were
systematically mapped in the 44 pairs of urine samples.
Figure 3 shows that expression levels of 91 identified pro-
teins significantly differed (p < 0.05). Of these, 83 were
upregulated (red shaded areas), and eight were down-
regulated (green shaded areas) proteins. Cluster analysis of
D/H ratios further revealed two subgroups of the 44 pa-
tients: a subgroup that had numerous upregulated proteins
(34 patients) and a subgroup that had relatively more
separate and distinct expression profiles (10 patients).
These differences suggest that, for early diagnosis, multi-
ple biomarkers may provide better prediction accuracy
compared to individual biomarkers.
Next, a GO analysis of the quantitative proteomics re-
sults was performed to pinpoint proteins and processes
underlying the changes in urinary proteomes observed in
HCC patients (Figure 4). Interestingly, proteins overex-
pressed (D/H > 1.5, p < 0.05) in HCC patients in compari-
son with healthy controls were linked to signal peptides,
response to wounding, acute inflammatory response, cal-
cium ion binding, and a-amylase activity (Figure 4A).
Figure 4B shows that downregulation of proteins was
significantly correlated with microtubule motor activity
with D/H < 0.5 and p < 0.05 and microtubule motor ac-
tivity. The roles of signal peptides, cytokines, and secreted
proteins have been studied extensively because of their
important roles in the HCC tumor microenvironment [4].
Therefore, urinary peptides may reflect signals or signa-
tures involved in cancer cellehost interaction and inflam-
matory process [52]. The criteria for further analysis of a
“hit” were penetrance of at least 50% and a D/H val-
ue > 1.5; of the 25 proteins that met these criteria
(Figure 4C), the top six were ROBO4, AXL, S100A9, TFF2,
ARSA, and GRN (Figure 4D). In adults, ROBO4 expression isreportedly confined to vasculature and is overexpressed in
tumor endothelial cells in comparison to normal endothelial
cells [56]. Several candidates were related to HCC prolif-
eration and invasion. The AXL promotes tumor invasion
through transcriptional activation of Slug in HCC, and
inhibiting AXL suppresses Slug expression and invasiveness
in HCC cell lines [57].
Use of onco-proteogenomics for discovering HCC
biomarkers
In recent years, HCC has been the most rapidly increasing
cause of cancer-related mortality in Taiwan [11] and the
United States (US) [58]. Because HCC is highly aggressive
Figure 4. Identification of top upregulated proteins in urine samples from HCC patients (nZ 44). Gene ontology analysis was
used to classify major functional processes among (A) 82 upregulated (D/H > 1.5, p < 0.05) and (B) seven downregulated (D/
H < 0.5, p < 0.05) proteins. (C) Upregulated proteins with at least 50% penetrance. The y axis is the frequency of upregulated
proteins (D/H > 1.5) identified in urine samples from HCC patients. (D) D/H values of top six candidates were obtained and selected
from individual sample pairs. HCCZ hepatocellular carcinoma.
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patients are ineligible for transplantation or liver resection.
Therefore, biomarkers for early detection and noninvasive
diagnosis and prognosis of HCC are urgently needed.
The use of recently developed proteomic methodolo-
gies, for example, shotgun proteomics, for qualitative and
quantitative analysis enable not only identification of pro-
tein mixtures in biological tissues with high reliability and
high throughput, but also comprehensive global analysis of
protein expression profiles in various cancer types,
including HCC [20e23]. However, a remaining obstacle to
using onco-proteomics to identify tumor-specific peptides is
the complexities of human cancer genomes and tran-
scriptomes, for example, point mutations, copy-number
aberrations, or unusual gene-splicing variants [24]. Onco-
proteogenomics is a new research strategy that solves this
problem by integrating proteomics, genomics, and tran-
scriptomics for detection of tumor-specific changes in the
proteome. Thus, onco-proteogenomics enables in-depth
understanding of the initiation and maintenance ofTable 1 Proteomic analysis identifies potential biomarkers for
Cancer Method Source
HCC Proteogenomics (shotgun proteomics
and stable isotope dimethyl labeling)
Urine from HCC
and healthy con
HCCZ hepatocellular carcinoma.tumors as well as their responses to drug treatments.
Notably, the United States National Cancer Institute has
established a proteogenomics program that integrates
cancer genomics and proteomics [59]. Combining MS-
generated data with genomic and transcriptomic informa-
tion, reveals how oncogenic signaling pathways are dysre-
gulated in various cancer types, including colorectal and
gastric cancer [30e32].
Because onco-proteogenomics technology enables large-
scale systematic monitoring of HCC genomes and corre-
sponding protein variations in the translational landscape
of cancer cells, onco-proteogenomics is an ideal tool for
identifying potential biomarkers for early diagnosis of HCC.
Notably, researchers have focused on identifying bio-
markers in urine, which is stable compared to other body
fluids and can be obtained noninvasively in large quantities.
Figure 4 and Table 1 show that the integration of proteo-
mic, genomic, and transcriptomic analyses in the proposed
proteogenomic approach revealed significantly higher co-
amplification of S100A9 and GRN (p < 0.001) andHCC.
Identified biomarkers Refs
patients
trols
Urinary S100A9 and GRN Huang et al, 2015 [55]
542 S.-H. Chiou, K.-T. Leesignificantly higher co-expression of S100A9 and GRN
(p < 0.01) in HCC tumors and urine samples compared to
controls. Notably, co-amplification of S100A9 and GRN was
also associated with poor survival in HCC patients. Overall,
our data suggest that S100A9 and GRN in urine have po-
tential use as combinatorial biomarkers for early diagnosis
of HCC. Our data also indicate the feasibility of using onco-
proteogenomics to elucidate the complex relationships
among proteomes and to identify protein biomarkers
applicable in patient-specific translational medicine, that
is, personalized translational therapy.Conclusion and future perspectives
Due to rapidly improving algorithms and software for
shotgun proteomic data analysis, the gel-free shotgun
approach to quantitative proteomics is now as accurate as
conventional shotgun genomic approaches. Given its ad-
vantages, the gel-free shotgun approach should be consid-
ered as the method of choice and preferred methodology
for elucidating the complex relationships between human
proteomes and various genome-related diseases. Methods
currently used for diagnosis and prognosis of HCC are
generally unsatisfactory because HCC is difficult to di-
agnose at an early stage, has a high recurrence rate after
surgery, and is resistant to chemotherapy. The aims of this
study were to provide an overview of newly developed
platforms for using highly sensitive noninvasive diagnostic
tools for profiling protein expression and to evaluate the
use of shotgun proteomics coupled with an integrated onco-
proteogenomics methodology, to improve understanding of
HCC carcinogenesis and progression and to discover novel
diagnostic and therapeutic methods. The focus of this study
was identifying and characterizing HCC biomarkers. By
examining and analyzing protein expression profiles in urine
and tissues from HCC patients and normal controls, we have
already positively identified two inflammation mediators,
that is, S100A9 and GRN. These protein biomarkers in the
alarmin family are found in most cells, especially immune
cells such as monocytes and macrophages. This group of
inducible endogenous cellular proteins or peptides is
secreted from cells upon infection or inflammation and has
a vital regulatory role in the host innate immune system
[59e70]. Thus, the HCC-associated cancer-specific bio-
markers described herein may contribute to dysregulatory
processes associated with inflammatory and autoimmune
conditions, as well as tumorigenesis and cancer metastasis.
Moreover, they have potential use as combinatorial bio-
markers for early diagnosis in personalized precision
medicine.Acknowledgments
This work was supported in part by the Kaohsiung Medical
University for the program of “Aim for the Top Universities
Grants” (Grant Nos. KMU-TP103E15 and KMU-TP104E20 to
S.-H.C.), the National Science Council (NSC Grant 102-2314-
B-037-037-MY2 to S.-H.C. and K.-T.L.), Ministry of Science
and Technology, Taipei, Taiwan (Grant Nos. MOST 103-2320-
B-037-021, MOST 104-2320-B-037-022, and MOST 104-2627-M-037-002 to S.-H.C.) and the Taiwan Protein Project of
Academia Sinica, funded by Ministry of Science and Tech-
nology (MOST105-0210-01-12-01). We also thank the tech-
nical support of Drs. C.-H. Huang and P.-J. Pai concerning
data analysis and manuscript preparation. The core facility
grant (NSC Grant 99-2745-B-037-005) of the Quantitative
Proteomics Center at the Center for Research Resources
and Development (CRRD), Kaohsiung Medical University was
under the auspices of National Science Council.References
[1] Aebersold R, Mann M. Mass spectrometry-based proteomics.
Nature 2003;422:198e207.
[2] Fehniger TE, Marko-Varga G. Proteomics and disease revisited:
the challenge of providing proteomic tools into clinical prac-
tice. J Proteome Res 2010;9:1191e2.
[3] Boja E, Hiltke T, Rivers R, Kinsinger C, Rahbar A, Mesri M,
et al. Evolution of clinical proteomics and its role in medicine.
J Proteome Res 2011;10:66e84.
[4] Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F,
Travali S, et al. The tumor microenvironment in hepatocel-
lular carcinoma (review). Int J Oncol 2012;40:1733e47.
[5] Chiou SH,WuCY.Clinical proteomics: current status, challenges,
and future perspectives. Kaohsiung J Med Sci 2011;27:1e14.
[6] Ansong C, Purvine SO, Adkins JN, Lipton MS, Smith RD. Proteo-
genomics: needs and roles to be filled by proteomics in genome
annotation. Brief Funct Genomic Proteomic 2008;7:50e62.
[7] Armengaud J.Proteogenomics and systemsbiology: quest for the
ultimate missing parts. Expert Rev Proteomics 2010;7:65e77.
[8] MannM,KulakNA,NagarajN,Cox J.Thecomingageofcomplete,
accurate, and ubiquitous proteomes. Mol Cell 2013;49:583e90.
[9] Renuse S, Chaerkady R, Pandey A. Proteogenomics. Prote-
omics 2011;11:620e30.
[10] Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies
for hepatocellular carcinoma: a critical view of the evidence.
Nat Rev Gastroenterol Hepatol 2013;10:34e42.
[11] Kee KM, Lu SN. Hospital- and community-based screenings for
hepatocellular carcinoma in Taiwan. Oncology 2011;81(Suppl.
1):36e40.
[12] Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis:
from genes to environment. Nat Rev Cancer 2006;6:674e87.
[13] Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular
carcinoma and consequences for treatment. Oncologist 2010;
15(Suppl. 4):14e22.
[14] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,
et al. Sorafenib in advanced hepatocellular carcinoma. N Engl
J Med 2008;359:378e90.
[15] Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG,
Evans MJ, et al. CDK9-mediated transcription elongation is
required for MYC addiction in hepatocellular carcinoma.
Genes Dev 2014;28:1800e14.
[16] Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET
pathway in hepatocellular carcinoma. Clin Cancer Res 2013;
19:2310e8.
[17] Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N,
et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of
response to systemic chemotherapy in patients with advanced
gastric cancer. Jpn J Clin Oncol 1999;29:550e5.
[18] Zhang B, Yang B. Combined alpha fetoprotein testing and ul-
trasonography as a screening test for primary liver cancer. J
Med Screen 1999;6:108e10.
[19] Chiou SH, Huang CH, Liang SS. From chemistry to translational
medicine: the application of proteomics to cancer biomarker
discovery and diagnosis. J Chin Chem Soc Taip 2015;62:217e26.
Proteomic analysis of hepatocellular carcinoma 543[20] Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK,
et al. Integrated genomic and proteomic analyses of a systemat-
ically perturbedmetabolic network. Science 2001;292:929e34.
[21] Washburn MP, Wolters D, Yates 3rd JR. Large-scale analysis of
the yeast proteome by multidimensional protein identification
technology. Nat Biotechnol 2001;19:242e7.
[22] McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G,
Drubin D, et al. Direct analysis and identification of proteins in
mixtures by LC/MS/MS and database searching at the low-
femtomole level. Anal Chem 1997;69:767e76.
[23] MacCoss MJ, McDonald WH, Saraf A, Sadygov R, Clark JM,
Tasto JJ, et al. Shotgun identification of protein modifications
from protein complexes and lens tissue. Proc Natl Acad Sci U S
A 2002;99:7900e5.
[24] Alfaro JA, Sinha A, Kislinger T, Boutros PC. Onco-proteoge-
nomics: cancer proteomics joins forces with genomics. Nat
Methods 2014;11:1107e13.
[25] Nesvizhskii AI. Proteogenomics: concepts, applications and
computational strategies. Nat Methods 2014;11:1114e25.
[26] Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D,
Binot F, et al. Genetic alterations associated with hepato-
cellular carcinomas define distinct pathways of hep-
atocarcinogenesis. Gastroenterology 2001;120:1763e73.
[27] Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and
EIF3S3 genes may be amplification targets at 8q23-q24 and are
associated with large hepatocellular carcinomas. Hepatology
2003;38:1242e9.
[28] Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, et al.
Identification of a therapeutic strategy targeting amplified
FGF19 in liver cancer by Oncogenomic screening. Cancer Cell
2011;19:347e58.
[29] Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP,
Chiang DY, et al. Integrative transcriptome analysis reveals
common molecular subclasses of human hepatocellular car-
cinoma. Cancer Res 2009;69:7385e92.
[30] Wang X, Slebos RJ, Wang D, Halvey PJ, Tabb DL, Liebler DC,
et al. Protein identification using customized protein
sequence databases derived from RNA-Seq data. J Proteome
Res 2012;11:1009e17.
[31] Halvey PJ, Wang X, Wang J, Bhat AA, Dhawan P, Li M, et al.
Proteogenomic analysis reveals unanticipated adaptations of
colorectal tumor cells to deficiencies in DNA mismatch repair.
Cancer Res 2014;74:387e97.
[32] Aquino PF, Lima DB, de Saldanha da Gama Fischer J,
Melani RD, Nogueira FC, Chalub SR, et al. Exploring the pro-
teomic landscape of a gastric cancer biopsy with the shotgun
imaging analyzer. J Proteome Res 2014;13:314e20.
[33] Kuo CJ, Liang SS, Hsi E, Chiou SH, Lin SD. Quantitative pro-
teomics analysis of varicose veins: identification of a set of
differentially expressed proteins related to ATP generation
and utilization. Kaohsiung J Med Sci 2013;29:594e605.
[34] Chiou SH, Lee MY, Kuo CJ, Liang SS. Application of quantita-
tive proteomics to disease diagnosis and prognosis using stable
isotope dimethyl labeling coupled with shotgun proteomics
strategy and multiple reaction monitoring. In: Li MD, editor.
Recent Advances in Proteomics Research. New York, U.S.A.:
Nova Science Publishers; 2013. p. 119e37.
[35] Liang SS, Kuo CJ, Chi SW, Wu WJ, Chen ST, Chiou SH. Quan-
titative proteomics analysis of differentially expressed pro-
teins involved in renal clear cell carcinoma by shotgun
approach coupled with stable isotope dimethyl labeling. J
Proteomics Bioinform 2013;S7:003.
[36] Kuo CJ, Wang SN, Liang SS, Chi SW, Yu ZJ, Hsi E, et al. Shotgun
proteomics analysis of differentially expressed urinary pro-
teins involved in the hepatocellular carcinoma. J Proteomics
Bioinform 2014;7:34e40.
[37] Lee MY, Huang CH, Kuo CJ, Lin CL, Lai WT, Chiou SH. Clinical
proteomics identifies urinary CD14 as a potential biomarkerfor diagnosis of stable coronary artery disease. PLoS One 2015;
10:e0117169.
[38] Kuo KK, Kuo CJ, Chiu CY, Liang SS, Huang CH, Chi SW, et al.
Quantitative proteomic analysis of differentially expressed
protein profiles involved in pancreatic ductal adenocarci-
noma. Pancreas 2016;45:71e83.
[39] Sze SK, Ge Y, Oh H, McLafferty FW. Top-down mass spec-
trometry of a 29-kDa protein for characterization of any
posttranslational modification to within one residue. Proc Natl
Acad Sci U S A 2002;99:1774e9.
[40] Kelleher NL. Top-down proteomics. Anal Chem 2004;76:
197ae203a.
[41] Bogdanov B, Smith RD. Proteomics by FTICR mass spectrom-
etry: top down and bottom up. Mass Spectrom Rev 2005;24:
168e200.
[42] Chait BT. Chemistry. Mass spectrometry: bottom-up or top-
down? Science 2006;314:65e6.
[43] Kovanich D, Cappadona S, Raijmakers R, Mohammed S,
Scholten A, Heck AJ. Applications of stable isotope dimethyl
labeling in quantitative proteomics. Anal Bioanal Chem 2012;
404:991e1009.
[44] Hsu JL, Huang SY, Chow NH, Chen SH. Stable-isotope dimethyl
labeling for quantitative proteomics. Anal Chem 2003;75:
6843e52.
[45] Boersema PJ, Raijmakers R, Lemeer S, Mohammed S, Heck AJ.
Multiplex peptide stable isotope dimethyl labeling for quan-
titative proteomics. Nat Protoc 2009;4:484e94.
[46] Boersema PJ, Aye TT, van Veen TA, Heck AJ, Mohammed S.
Triplex protein quantification based on stable isotope labeling
by peptide dimethylation applied to cell and tissue lysates.
Proteomics 2008;8:4624e32.
[47] DeSouza LV, Siu KW. Mass spectrometry-based quantification.
Clin Biochem 2013;46:421e31.
[48] Ting L, Rad R, Gygi SP, Haas W. MS3 eliminates ratio distortion
in isobaric multiplexed quantitative proteomics. Nat Methods
2011;8:937e40.
[49] Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based
protein identification by searching sequence databases using
mass spectrometry data. Electrophoresis 1999;20:3551e67.
[50] Hirosawa M, Hoshida M, Ishikawa M, Toya T. MASCOT: multiple
alignment system for protein sequences based on three-way
dynamic programming. Comput Appl Biosci 1993;9:161e7.
[51] Huang da W, Sherman BT, Lempicki RA. Systematic and inte-
grative analysis of large gene lists using DAVID bioinformatics
resources. Nat Protoc 2009;4:44e57.
[52] Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients.
Cancer Res 2010;70:10202e12.
[53] Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, et al.
Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepa-
titis B virus infection and hepatocellular carcinoma in Taiwan.
Carcinogenesis 2008;29:971e6.
[54] Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R,
Grassi M, et al. Novel hepatocellular carcinoma molecules
with prognostic and therapeutic potentials. World J Gastro-
enterol 2014;20:1268e88.
[55] Huang CH, Kuo CJ, Liang SS, Chi SW, Hsi E, Chen CC, et al.
Onco-proteogenomics identifies urinary S100A9 and GRN as
potential combinatorial biomarkers for early diagnosis of he-
patocellular carcinoma. BBA Clin 2015;3:205e13.
[56] Avci ME, Konu O, Yagci T. Quantification of SLIT-ROBO tran-
scripts in hepatocellular carcinoma reveals two groups of
genes with coordinate expression. BMC cancer 2008;8:392.
[57] Lee HJ, Jeng YM, Chen YL, Chung L, Yuan RH. Gas6/Axl
pathway promotes tumor invasion through the transcriptional
activation of Slug in hepatocellular carcinoma. Carcinogenesis
2014;35:769e75.
544 S.-H. Chiou, K.-T. Lee[58] El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;
365:1118e27.
[59] Rivers RC, Kinsinger C, Boja ES, Hiltke T, Mesri M, Rodriguez H.
Linking cancer genome to proteome: NCI’s investment into
proteogenomics. Proteomics 2014;14:2633e6.
[60] Nie Y, Yang D, Oppenheim JJ. Alarmins and antitumor immu-
nity. Clin Ther 2016;38:1042e53.
[61] Arshad MI, Khan HA, Noel G, Piquet-Pellorce C, Samson M. Po-
tential therapeutic aspects of alarmin cytokine interleukin 33 or
its inhibitors in various diseases. Clin Ther 2016;38. 1000e16.e1.
[62] Villarreal DO, Siefert RJ, Weiner DB. Alarmin IL-33 elicits
potent TB-specific cell-mediated responses. Hum Vaccin
Immunother 2015;11:1954e60.
[63] Theoharides TC, Petra AI, Taracanova A, Panagiotidou S,
Conti P. Targeting IL-33 in autoimmunity and inflammation. J
Pharmacol Exp Ther 2015;354:24e31.
[64] Steichen AL, Simonson TJ, Salmon SL, Metzger DW, Mishra BB,
Sharma J. Alarmin function of galectin-9 in murine respiratory
tularemia. PLoS One 2015;10:e0123573.
[65] Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi SM,
Fumagalli G, et al. Inflammatory molecules in frontotemporaldementia: cerebrospinal fluid signature of progranulin muta-
tion carriers. Brain Behav Immun 2015;49:182e7.
[66] Li N, Yamasaki K, Saito R, Fukushi-Takahashi S, Shimada-
Omori R, Asano M, et al. Alarmin function of cathelicidin
antimicrobial peptide LL37 through IL-36gamma induction in
human epidermal keratinocytes. J Immunol 2014;193:
5140e8.
[67] Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial
roles in innate immunity, inflammation and allergy. Curr Opin
Immunol 2014;31:31e7.
[68] Diener KR, Al-Dasooqi N, Lousberg EL, Hayball JD. The
multifunctional alarmin HMGB1 with roles in the patho-
physiology of sepsis and cancer. Immunol Cell Biol 2013;91:
443e50.
[69] Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW,
Teale JM, et al. Galectin-3 functions as an alarmin: patho-
genic role for sepsis development in murine respiratory tula-
remia. PLoS One 2013;8:e59616.
[70] Oppenheim JJ, Tewary P, de la Rosa G, Yang D. Alarmins
initiate host defense. Adv Exp Med Biol 2007;601:185e94.
